The results indicated that pre‐treatment with PLCβ, PKCα and c‐Src inhibitors (U73122, GF109203X and PP2) reversed CXCL13‐promoted cell migration and VCAM‐1 in lung cancer cells (Figure 5A,B). This evidence concerns the gene CXCL13 and lung carcinoma.